Metabolic / Weight Management
Efpeglenatide
Efpeglenatide is a long-acting, exendin-based GLP-1 receptor agonist investigated for the management of type 2 diabetes and obesity.
Evidence: 0 articles
Goals: 0
Mechanism of Action
Efpeglenatide acts as a selective agonist for the GLP-1 receptor. By mimicking the action of endogenous GLP-1, it stimulates glucose-dependent insulin secretion, suppresses inappropriate glucagon secretion, slows gastric emptying, and promotes satiety, thereby improving glycemic control and potentially reducing body weight.
Evidence Level
Clinical Trial - Human
0 studies published